Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||HFB200301 + Tislelizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|HFB200301||HFB 200301|HFB-200301||HFB200301 is an antibody that targets TNFR2, potentially resulting in enhanced anti-tumor immune response (Cancer Res (2021) 81 (13_Supplement): 1883).|
|Tislelizumab||BGB-A317||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05238883||Phase I||HFB200301 HFB200301 + Tislelizumab||A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors||Recruiting||USA | ESP||0|